Capecitabine
Brand Name: Xeloda
Manufacturer:
Indication
Indication:
Used to treat colorectal cancer in both the adjuvant and metastatic settings. It is used as a single agent (monotherapy) for stage III colon cancer after surgical resection and in combination regimens such as CAPOX (capecitabine plus oxaliplatin) for the treatment of stage III colon cancer and metastatic colorectal cancer (mCRC). Capecitabine may also be used as a fluoropyrimidine backbone in metastatic disease when oral therapy is preferred, offering an alternative to intravenous fluorouracil.
Specific CRC Subtype: None
Stage: II, III, IV
Therapy Line: First-line, Third-line or later
Health Canada Approval: Approved
pCPA Negotiation Status:
Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan), YU (Yukon)
New Search
